CinCor Plans Baxdrostat Phase III Despite Phase II Miss In Uncontrolled Hypertension

CinCor Pharma, Inc. has been busy raising cash on the promise of its selective aldosterone synthase inhibitor baxdrostat this year, but a missed primary endpoint in a Phase II study in uncontrolled hypertension has some investors second-guessing their decisions. However, the Waltham, MA-based firm is hoping that success in an earlier Phase II study in treatment-resistant hypertension, a prespecified subgroup analysis from the more recent study and a theory about non-adherence to background therapy might combine to support a Phase III program next year.

On 28 November, CinCor reported that baxdrostat (CIN-107), licensed from Roche Holding AG in 2019 for investigation in high blood pressure indications as well as primary aldosteronism, failed to hit the endpoint of change from baseline in mean seated systolic blood pressure (SSBP) compared to placebo at eight weeks. (Also see "Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech" - Scrip, 17 May, 2019